Want to join the conversation?
$MYL announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of $CELG's Vidaza Injection, 100 mg/vial. Azacitidine for Injection is nucleoside metabolic inhibitor indicated for treatment of 5 French-American-British (FAB) subtypes of myelodysplastic syndrome, blood cell disorder occur for cancer treatments.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.